Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Issue 3 (28th September 2016)

• Record Type: Journal Article
• Authors: Lizak, Nathaniel; Lugaresi, Alessandra; Alroughani, Raed; Lechner-Scott, Jeannette; Slee, Mark; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Izquierdo, Guillermo; Duquette, Pierre; Girard, Marc; Prat, Alexandre; Grammond, Pierre; Hupperts, Raymond; Grand'Maison, Francois; Sola, Patrizia; Pucci, Eugenio; Bergamaschi, Roberto; Oreja-Guevara, Celia; Van Pesch, Vincent; Ramo, Cristina; Spitaleri, Daniele; Iuliano, Gerardo; Boz, Cavit; Granella, Franco; Olascoaga, Javier; Verheul, Freek; Rozsa, Csilla; Cristiano, Edgardo; Flechter, Shlomo; Hodgkinson, Suzanne; Amato, Maria Pia; Deri, Norma; Jokubaitis, Vilija; Spelman, Tim; Butzkueven, Helmut; Kalincik, Tomas;
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 88:Issue 3(2017)
• Page Start: 196
• Page End: 203
• Publication Date: 2016-09-28
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2016-313976
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objective: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. Methods: The epochs between Expanded Disability Status Scale (EDSS) steps 3–6, 4–6 and 6–6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and inclusion criteria were conducted. Results: For the EDSS 3–6, 4–6 and 6–6.5 epochs, 1560, 1504 and 1231 patients were identified, respectively. Disability trajectories showed large coefficients of variance prebaseline (0.92–1.11) and postbaseline (2.15–2.50), with no significant correlations. The probability of reaching the outcome step was not associated with prebaseline variables, but was increased by higher relapse rates during each epoch (HRs 1.58–3.07; p<0.001). A greater proportion of each epoch treated with higher efficacy therapies was associated with lower risk of reaching the outcome disability step (HRs 0.72–0.91 per 25%; p≤0.02). 3 sensitivity analyses confirmed these results. Conclusions: Disease progression during moderately advanced and advanced MS is highly variable and amnesic to prior disease activity. Lower relapse rates and greater time on higher efficacy immunomodulatory therapy after reaching EDSS steps 3, 4 and 6 are associated with a decreased risk of accumulating further disability. Highly effective immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced relapse-onset MS.